Search research articles
Contact Us
Filters
Showing results (271-280 of 379) with videos related to
Page
of 38
Sort By:
Cancer Research
|
January 11, 2007
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro
Dennis A Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, et al.
Blood
|
July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Ajay K Gopal, Scott E Smith, et al.
British Journal of Haematology
|
December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial
Boris Böll, Annette Plütschow, Carolin Bürkle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
Paul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission
Sebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
Blood
|
December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K Gopal, Robert Chen, Scott E Smith, et al.
The Lancet. Haematology
|
October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials
Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood
|
January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
Anas Younes, Anna Sureda, Dina Ben-Yehuda, et al.
Page
of 38
Search research articles
Search
Showing results (271-280 of 379) with videos related to
Sort By:
Page
of 38
Cancer Research
|
January 11, 2007
ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro
Dennis A Eichenauer, Vijaya Lakshmi Simhadri, Elke Pogge von Strandmann, et al.
Blood
|
July 20, 2016
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Ajay K Gopal, Scott E Smith, et al.
British Journal of Haematology
|
December 29, 2018
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial
Boris Böll, Annette Plütschow, Carolin Bürkle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 15, 2020
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
Paul J Bröckelmann, Horst Müller, Teresa Guhl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 28, 2012
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission
Sebastian Theurich, Joke Malcher, Kerstin Wennhold, et al.
Blood
|
December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K Gopal, Robert Chen, Scott E Smith, et al.
The Lancet. Haematology
|
October 7, 2018
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials
Bastian von Tresckow, Stefanie Kreissl, Helen Goergen, et al.
European Journal of Haematology
|
September 3, 2022
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
Sarah Gillessen, Annette Pluetschow, Vladan Vucinic, et al.
Blood
|
January 31, 2014
Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
Dennis A Eichenauer, Indra Thielen, Heinz Haverkamp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2012
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study
Anas Younes, Anna Sureda, Dina Ben-Yehuda, et al.
Page
of 38